Relief Therapeutics Holding SA / CH1251125998

  Shareholders approved all proposals by a large majority GENEVA (June 12, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the results of its annual general meeting (AGM) of shareholders, held earlier today in Geneva. All proposed resolutions were approved by more than 85 percent of the represented votes. AGM Results       Annual Report and Financial Statements for the Year 2024 The AGM approved the 2024 annual report and financial statements.       Appropriation of Available Earnings The AGM approved carrying forward the net result for the 2024 financial year.       Discharge of the Board of Directors and the Executive Committee The AGM granted discharge to the board of directors and the executive committee for the 2024 financial year.       Elections to the Board of Directors The AGM re-elected Dr. Raghuram Selvaraju, Mr. Gregory Van Beek, Mr. Peter de Svastich, and Mr. Thomas Elzinga to the board of directors. Dr. Selvaraju was re-elected as chairman of the board. Mr. de Svastich and Dr. Selvaraju were re-elected as members of the nomination and compensation committee.       Compensation of the members of the Board of Directors and of the Executive Committee The AGM approved the proposed maximum compensation amounts for the board of directors for the period from AGM 2025 to AGM 2026, and for the executive committee for the 2026 financial year. Shareholders also approved, on a consultative basis, the 2024 compensation report.       Independent Voting Rights Representative The AGM re-elected Mr. Thomas Hua as the Company’s independent proxy.       Auditors The AGM re-elected FORVIS MAZARS SA as the Company’s statutory auditor.
The full text of the resolutions submitted to shareholders is available in the AGM Invitation. The detailed voting results will be published on the Company’s website later today.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief’s clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com DISCLAIMER
This press release may contain forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.